Aspirin’s long held promises are increasingly falling flat. A natural, safer and more effective alternative to this synthetic drug has been known about for at least 15 years!
In a previous article titled “The Evidence Against Aspirin and For Natural Alternatives,” we discussed the clear and present danger linked with the use of aspirin as well as several clinically proven alternatives that feature significant side benefits as opposed to aspirin’s many known side effects.
Since writing this article, even more evidence has accumulated indicating that aspirin’s risks outweigh its benefits. Most notably, a 15-year Dutch study published in the journal Heart found that among 27,939 healthy female health professionals (average age 54) randomized to receive either 100 mg of aspirin every day or a placebo the risk of gastrointestinal bleeding outweighed the benefit of the intervention for colorectal cancer and cardiovascular disease prevention in those under 65 years of age.
Of course, aspirin is not alone as far as dangerous side effects are concerned. The entire non-steroidal anti-inflammatory (NSAID) category of prescription and over-the-counter drugs is wrought with serious danger. Ibuprofen, for instance, is known to kill thousands each year, and is believed no less dangerous than Merck’s COX-2 inhibitor NSAID drug Vioxx which caused between 88,000-140,000 cases of serious heart disease in the five years it was on the market (1999-2004). Tylenol is so profoundly toxic to the liver that contributing writer Dr. Michael Murray recently asked in his Op-Ed piece, “Is it Time for the FDA to Remove Tylenol From the Market?“
Given the dire state of affairs associated with pharmaceutical intervention for chronic pain issues, what can folks do who don’t want to kill themselves along with their pain?
Pine Bark Extract (Pycnogenol) Puts Aspirin To Shame
When it comes to aspirin alternatives, one promising contender is pycnogenol, a powerful antioxidant extracted from French maritime pine back, backed by over 40 years of research, the most compelling of which we have aggregated on GreenMedInfo.com here: Pycnogenol Research. Amazingly, you will find research indexed there showing it may have value for over 80 health conditions.
In 1999, a remarkable study published in the journal Thrombotic Research found that pycnogenol was superior (i.e. effective at a lower dosage) to aspirin at inhibiting smoking-induced clotting, without the significant (and potentially life-threatening) increase in bleeding time associated with aspirin use. The abstract is well worth reading in its entirety:
“The effects of a bioflavonoid mixture, Pycnogenol, were assessed on platelet function in humans. Cigarette smoking increased heart rate and blood pressure. These increases were not influenced by oral consumption of Pycnogenol or Aspirin just before smoking. However, increased platelet reactivity yielding aggregation 2 hours after smoking was prevented by 500 mg Aspirin or 100 mg Pycnogenol in 22 German heavy smokers. In a group of 16 American smokers, blood pressure increased after smoking. It was unchanged after intake of 500 mg Aspirin or 125 mg Pycnogenol. In another group of 19 American smokers, increased platelet aggregation was more significantly reduced by 200 than either 150 mg or 100 mg Pycnogenol supplementation. This study showed that a single, high dose, 200 mg Pycnogenol, remained effective for over 6 days against smoking-induced platelet aggregation. Smoking increased platelet aggregation that was prevented after administration of 500 mg Aspirin and 125 mg Pycnogenol. Thus, smoking-induced enhanced platelet aggregation was inhibited by 500 mg Aspirin as well as by a lower range of 100-125 mg Pycnogenol. Aspirin significantly (p<0.001) increased bleeding time from 167 to 236 seconds while Pycnogenol did not. These observations suggest an advantageous risk-benefit ratio for Pycnogenol.” [emphasis added]”
As emphasized in bold above, pycnogenol unlike aspirin did not significantly increase bleeding time. This has profound implications, as aspirin’s potent anti-platelet/’blood thinning’ properties can also cause life-threatening hemorrhagic events. If this study is accurate and pycnogenol is more effective at decreasing pathologic platelet aggregation at a lower dose without causing the increased bleeding linked to aspirin, then it is clearly a superior natural alternative worthy of far more attention by the conventional medical establishment and research community than it presently receives.
Not Just A Drug Alternative
Pycnogenol, like so many other natural interventions, has a wide range of side benefits that may confer significant advantage when it comes to reducing cardiovascular disease risk. For instance, pycnogenol is also:
- Blood Pressure Reducing/Endothelial Function Enhancer: A number of clinical studies indicate that pycnogenol is therapeutic for those suffering with hypertension. Pycnogenol actually addresses a root cause of hypertension and cardiovascular disease in general, namely, endothelial dysfunction (the inability of the inner lining of the blood vessels to function correctly, e.g. fully dilate). It has been shown to prevent damage in microcirculation in hypertensive patients, as well as reducing the dose of blood pressure drugs in hypertensive patients, including hypertensive diabetic patients. It has even been found to reduce intraocular hypertension found in glaucoma patients.
- Anti-Inflammatory Effects: There is a growing appreciation among the medical community that inflammation contributes to cardiovascular disease. Several markers, including C-reactive protein are now being fore grounded as being at least as important in determining cardiovascular disease risk as various blood lipids and/or their ratios, such as low-density lipoprotein (LDL). Pycnogenol has been found to reduce C-reactive protein in hypertensive patients. Pycnogenol has been found to rapidly modulate downward (inhibit) both Cox-1 and Cox-2 enzyme activity in human subjects, resulting in reduced expression of these inflammation-promoting enzymes within 30 minutes post-ingestion. Another observed anti-inflammatory effect of pycnogenol is its ability to down-regulate the class of inflammatory enzymes known as matrix metalloproteinases (MMPs). Pycnogenol has also been found to significantly inhibit NF-kappaB activation, a key body-wide regulator of inflammation levels whose overexpression and/or dysregulation may result in pathologic cardiovascular manifestations. Finally, pycnogenol has been found to reduce fibrinogen levels, a glycoprotein that contributes to the formation of blood clots; fibrinogen has been identified as an independent risk factor for cardiovascular disease.
Given the evidence for pycnogenol’s pleotrophic cardioprotective properties, we hope that pycnogenol will become more commonly recommended by health care practitioners as the medical paradigm continues to evolve past its reliance on synthetic chemicals, eventually (we hope) returning to natural, increasingly evidence-based interventions. However, it is important that we don’t fall prey to the one-disease-one-pill model, convincing ourselves to focus on popping pills – this time natural ones – as simply countermeasures or ‘insurance’ against the well known harms associated with the standard American diet, lack of exercise, and uncontrolled stress. The ultimate goal is to remove the need for pills altogether, focusing on preventing cardiovascular disease from the ground up and inside out, e.g. letting high quality food, clean water and air, and a healthy attitude nourish and sustain our health and well-being.
Note: Are you suffering from chronic pain issues and looking for root cause resolution of your symptoms using natural interventions? Don’t forget to join the upcoming, free online Pain Relief Project conference. Save your spot by registering for free here.
 Gianni Belcaro, Maria Rosaria Cesarone, Andrea Ricci, Umberto Cornelli, Peter Rodhewald, Andrea Ledda, Andrea Di Renzo, Stefano Stuard, Marisa Cacchio, Giulia Vinciguerra, Giuseppe Gizzi, Luciano Pellegrini, Mark Dugall, Filiberto Fano. Control of edema in hypertensive subjects treated with calcium antagonist (nifedipine) or angiotensin-converting enzyme inhibitors with Pycnogenol. Clin Appl Thromb Hemost. 2006 Oct;12(4):440-4. PMID: 17000888
 Sherma Zibadi, Peter J Rohdewald, Danna Park, Ronald Ross Watson. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res. 2008 May;28(5):315-20. PMID: 19083426
 Robert D Steigerwalt, Belcaro Gianni, Morazzoni Paolo, Ezio Bombardelli, Carolina Burki, Frank Schönlau. Effects of Mirtogenol on ocular blood flow and intraocular hypertension in asymptomatic subjects. Mol Vis. 2008;14:1288-92. Epub 2008 Jul 10. PMID: 18618008
 Maria Rosaria Cesarone, Gianni Belcaro, Stefano Stuard, Frank Schönlau, Andrea Di Renzo, Maria Giovanna Grossi, Mark Dugall, Umberto Cornelli, Marisa Cacchio, Giuseppe Gizzi, Luciano Pellegrini. Kidney flow and function in hypertension: protective effects of pycnogenol in hypertensive participants–a controlled study. J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):41-6. Epub 2010 Jan 22. PMID: 20097689
 Angelika Schäfer, Zuzana Chovanová, Jana Muchová, Katarína Sumegová, Anna Liptáková, Zdenka Duracková, Petra Högger. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother. 2006 Jan;60(1):5-9. Epub 2005 Oct 26. PMID: 16330178
 Tanja Grimm, Angelika Schäfer, Petra Högger. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Wei Sheng Yan Jiu. 2011 Jan;40(1):103-6. PMID: 14990359
 Tanja Grimm, Zuzana Chovanová, Jana Muchová, Katarína Sumegová, Anna Liptáková, Zdenka Duracková, Petra Högger. Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm (Lond). 2006;3:1. Epub 2006 Jan 27. PMID: 16441890
 G Belcaro, M R Cesarone, S Errichi, C Zulli, B M Errichi, G Vinciguerra, A Ledda, A Di Renzo, S Stuard, M Dugall, L Pellegrini, G Gizzi, E Ippolito, A Ricci, M Cacchio, G Cipollone, I Ruffini, F Fano, M Hosoi, P Rohdewald. Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. Redox Rep. 2008;13(6):271-6. PMID: 19017467
© June 30, 2018 GreenMedInfo LLC. This work is reproduced and distributed with the permission of GreenMedInfo LLC. Want to learn more from GreenMedInfo? Sign up for the newsletter here http://www.greenmedinfo.com/greenmed/newsletter.